Ongoing Symptoms After Acute SARS-CoV-2 or Influenza Infection in a Case-Ascertained Household Transmission Study: 7 US Sites, 2021–2023
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Ayla Bullock und 24 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Global Health and Infectious Disease, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Influenza, Human, COVID-19. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Background
The prevalence and risk factors for ongoing symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [SCV2]) or influenza infection are not well characterized. We conducted a prospective cohort study of households wherein ≥1 individual was infected with SCV2 or influenza to evaluate prevalence of and factors associated with ongoing symptoms at 90 days.
Methods
Index cases and their household contacts provided baseline health and sociodemographic information and collected daily respiratory specimens for 10 days following enrollment. Participants completed a follow-up survey 90 days after enrollment to characterize ongoing symptoms.
Results
We analyzed 1967 participants enrolled between December 2021 and May 2023. The risk of ongoing symptoms did not differ by infection status in SCV2 (SCV2-positive: 15.6%; SCV2-negative: 13.9%; odds ratio [OR]: 1.14; 95% CI: .7–1.69) or influenza (influenza-positive: 8.8%; influenza-negative: 10.0%; OR: .87; 95% CI: .45–1.72) households. However, among study participants with a documented infection, SCV2-positive participants had nearly twice the odds of ongoing symptoms as influenza-positive participants (OR: 1.92; 95% CI: 1.27–2.97).
Conclusions
These results suggest that SCV2 households have a significantly higher prevalence of ongoing symptoms compared with influenza households (OR: 1.78; 95% CI: 1.28–2.47). Among participants with SCV2 infection, underlying conditions (adjusted OR [aOR]: 2.65; 95% CI: 1.80–3.90) and coronavirus disease 2019 (COVID-19)–like symptoms (aOR: 2.92; 95% CI: 1.15–7.43) during acute infection increased odds of ongoing symptoms at 90 days, whereas hybrid immunity reduced the odds of ongoing symptoms (aOR: 0.44; 95% CI: .22–.90).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute for Global Health and Infectious Disease, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
- National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Department of Pediatrics, Columbia University Irving Medical Centre, New York, New York, USA.
- Department of Emergency Medicine, Columbia University Irving Medical Center, New York, New York, USA.
- Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, Wisconsin, USA.
- Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado, USA.
ORCID-Profile: Ayla Bullock, Alexandra F Dalton, Melissa S Stockwell, Son H McLaren, Ellen Sano, Huong Q Nguyen, Suchitra Rao, Edwin Asturias, Karen Lutrick, Yvonne Maldonado, Sarah E Smith-Jeffcoat, Carlos G Grijalva, H Keipp Talbot, Jessica E Biddle, Yuwei Zhu, Kathleen Pryor, Joshua G Petrie, Michelle Floris-Moore
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Bullock, A., Dalton, A. F., Stockwell, M. S., McLaren, S. H., Sano, E., Nguyen, H. Q., Rao, S., Asturias, E., Lutrick, K., Ellingson, K. D., Maldonado, Y., Mellis, A. M., Smith-Jeffcoat, S. E., Grijalva, C. G., Talbot, H. K., Rolfes, M. A. R., Biddle, J. E., Zhu, Y., Ledezma, K., …, & Bowman, N. (2025). Ongoing Symptoms After Acute SARS-CoV-2 or Influenza Infection in a Case-Ascertained Household Transmission Study: 7 US Sites, 2021–2023. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf026
Vancouver
Bullock A, Dalton AF, Stockwell MS, McLaren SH, Sano E, Nguyen HQ, et al. Ongoing Symptoms After Acute SARS-CoV-2 or Influenza Infection in a Case-Ascertained Household Transmission Study: 7 US Sites, 2021–2023. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf026
BibTeX
@article{Bullock2025,
author = {Bullock, Ayla and Dalton, Alexandra F and Stockwell, Melissa S and McLaren, Son H and Sano, Ellen and Nguyen, Huong Q and Rao, Suchitra and Asturias, Edwin and Lutrick, Karen and Ellingson, Katherine D and Maldonado, Yvonne and Mellis, Alexandra M and Smith-Jeffcoat, Sarah E and Grijalva, Carlos G and Talbot, H Keipp and Rolfes, Melissa A R and Biddle, Jessica E and Zhu, Yuwei and Ledezma, Karla and Pryor, Kathleen and Valdez de Romero, Ana and Vargas, Celibell and Petrie, Joshua G and Floris-Moore, Michelle and Bowman, Natalie},
title = {Ongoing Symptoms After Acute SARS-CoV-2 or Influenza Infection in a Case-Ascertained Household Transmission Study: 7 US Sites, 2021–2023},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf026}
}
EUVIMED